The diabetes prevention program and its global implications

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Molitch, Mark E ^d   Fujimoto, Wilfred ^a   Hamman, Richard F ^b   Knowler, William C ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; PLACEBO; TROGLITAZONE;

ADULT; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG UTILIZATION; ETHNIC DIFFERENCE; FAT INTAKE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY FAILURE; LIFESTYLE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOMES RESEARCH; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; WEIGHT REDUCTION;

EID: 0037868057     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 28: 518-524, 1998
2. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431, 1998
3. Cockram CS: The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 6: 43-52, 2000
4. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795-808, 1999
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
6. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998
7. Knowler WC, Narayan KM, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Schersten B, Pettitt DJ: Preventing non-insulin-dependent diabetes. Diabetes 44: 483-488, 1995
8. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases: The prevention or delay of type 2 diabetes. Diabetes Care 25: 742-749, 2002
9. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281-303, 1999
10. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes 46: 701-710, 1997
11. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345: 790-797, 2001
12. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22: 623-634, 1999
13. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197, 1997
15. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23: 1619-1629, 2000
16. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001
17. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544, 1997
18. nd Ed., National Diabetes Data Group, NIH Publication #95-1468, 1995, pp 349-385
19. Pugh JA, Medina RA, Cornell JC, Basu S: NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community. Diabetes 44: 1375-1380, 1995
20. Karter AJ, Ferrara A, Liu JY Moffet HH, Ackerson LM, Selby JV: Ethnic disparities in diabetic complications in an insured population. JAMA 287: 2519-2527, 2002
21. United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317: 703-713, 1998
22. United Kingdom Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. (UKPDS 39). BMJ 317: 713-720, 1998
23. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with Type 2 diabetes. N Engl J Med 346: 1145-1151, 2002
24. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20: 735-744, 1997
25. The CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for Type 2 diabetes. JAMA 287: 2542-2551, 2002
26. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health: Physical activity and cardiovascular health. JAMA 276: 241-246, 1996